The SBC Medical Group Holdings Incorporated (Nasdaq: SBC) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer with associated redeemable warrants trading under the symbol SBCWW, SBC submits a range of filings that document its financial condition, material events, and capital markets activity.
Among the most relevant documents for investors are current reports on Form 8-K, which SBC uses to announce material events such as quarterly financial results, tender offers and acquisitions, index inclusions, and capital strategy updates. For example, the company has filed 8-K reports to furnish press releases on quarterly results, to describe its inclusion in the Russell 3000 Index, and to summarize a tender offer for shares of Waqoo, Inc., a regenerative medicine research and development company. These filings provide detail on SBC’s operating performance, investment activities, and strategic direction.
Investors can also review filings related to capital structure and financing, including registration statements such as the company’s shelf registration on Form S-3. That registration statement, referenced in SBC’s news releases and 8-K filings, enables the company to offer and sell specified amounts of common and preferred stock in future offerings and also covers securities associated with its prior business combination transaction.
On Stock Titan, SBC’s filings are complemented by AI-powered summaries designed to help readers interpret complex regulatory documents. These summaries highlight key points from lengthy filings, such as the nature of material events disclosed in Form 8-K, the scope of registered securities in shelf filings, and the implications of tender offers or strategic investments. The page updates as new SBC filings are posted to the SEC’s EDGAR system, giving users a centralized view of the company’s regulatory history and ongoing disclosure record.
On behalf of SBC Medical Group Holdings Incorporated, the board is soliciting proxies for the 2026 annual meeting to be held virtually at 9:00 a.m. JST on July 9, 2026 (8:00 p.m. ET on July 8, 2026). Four directors will be elected, MaloneBailey, LLP is proposed for ratification as independent auditor for fiscal year ending December 31, 2026, and stockholders are asked to approve multiple charter amendments, including elimination of plurality voting, removal-for-cause limitation, opting out of Section 203 of the DGCL, officer exculpation, and other technical changes.
The record date for voting is May 20, 2026; there were 102,576,943 shares outstanding as of that date (after deducting 270,000 shares held by a wholly-owned subsidiary). The board recommends a FOR vote on all proposals.
SBC Medical Group Holdings reported first-quarter 2026 total revenue of $43.1 million, down from $47.3 million a year earlier, as related-party revenues softened while third-party revenues grew. Gross profit declined to $30.3 million from $37.7 million, reflecting higher cost of revenues.
Income from operations fell to $17.7 million from $24.2 million. Net income attributable to SBC decreased to $11.3 million versus $21.5 million, and basic and diluted EPS declined to $0.11 from $0.21, partly because the prior-year period included a sizable gain on redemption of life insurance policies.
Despite lower earnings, operating cash flow strengthened to $9.2 million from $1.9 million, helped by working capital movements and lower income tax payments. Cash and cash equivalents rose to $167.3 million as of March 31, 2026, and total assets reached $388.0 million with total liabilities of $117.6 million. Stockholders’ equity increased to $270.4 million. Weighted average shares outstanding were 102,576,943 for the quarter, and net income included modest non-controlling interest allocations.
SBC Medical Group Holdings reported first quarter 2026 revenue of $43.1 million, a 9% year-over-year decline driven mainly by an April 2025 revision of its franchise fee structure. Net income attributable to the company was $11.3 million, down 47%, with net income margin falling to 26%, a 19‑point decrease.
EPS was $0.11, a 48% decline versus a year earlier. Despite the weaker profits, EBITDA was $18.4 million with a still-strong 43% EBITDA margin, and annualized return on equity was 18%. The business continued to expand operationally, with 284 franchise locations (up 33 year over year), 6.76 million customers over the last twelve months (up 10%), and a 72% customer repeat rate. The balance sheet showed cash and cash equivalents of $167.3 million and total assets of $388.0 million, while operating cash flow for the quarter was $9.2 million. Management highlighted ongoing focus on multi-brand expansion, non-aesthetic medical services, overseas growth, and AI-enabled longevity and healthcare offerings.
SBC Medical Group Holdings filed Amendment No. 1 to its 2025 annual report to add detailed Part III disclosures on directors, executive compensation, ownership and related‑party transactions. The amendment also updates the April 29, 2026 outstanding share count to 102,576,943 and clarifies that no information is incorporated by reference. It does not change previously reported 2025 financial results.
The filing shows CEO Yoshiyuki Aikawa controls about 81.7% of voting power and received a $12,000,000 base salary in 2025. SBC describes its board committees, controlled‑company status under Nasdaq rules, employment agreements with key executives, and extensive revenue and financing relationships with Japanese medical corporations and other entities related to the CEO and his family.
SBC Medical Group Holdings Inc Chairman and CEO Yoshiyuki Aikawa reported an open-market sale of 465,000 shares of common stock on April 28, 2026 at a net price of $3.0225 per share. The sale occurred on the closing date of the underwriters' option to purchase additional shares tied to an underwritten public offering that initially closed on April 21, 2026.
Following the transaction, Aikawa holds 78,839,460 SBC shares directly, plus indirect interests including 5,000,000 shares held by Aikawa Investment Co., Ltd., which he wholly owns, and an 861,600-share indirect interest through Aikawa Equity Management Co., Ltd., where he disclaims beneficial ownership except for his pecuniary interest.
SBC Medical Group Holdings Inc Chairman and CEO Yoshiyuki Aikawa sold 3,100,000 shares of common stock at a net price of $3.0225 per share in an underwritten public offering that closed on April 21, 2026.
Following the sale, he holds 79,304,460 SBC shares directly, plus 5,000,000 shares indirectly through Aikawa Investment Co., Ltd., a company he wholly owns. He also reports an indirect interest corresponding to 861,600 shares held by Aikawa Equity Management Co., Ltd., while disclaiming beneficial ownership beyond his pecuniary interest.
SBC Medical Group Holdings Incorporated entered into an underwriting agreement for an underwritten secondary offering of 3,100,000 shares of its common stock by CEO and chairman Dr. Yoshiyuki Aikawa as selling stockholder. The underwriters also received a 45-day option to buy up to an additional 465,000 shares.
The offering closed on April 21, 2026. The company did not sell any shares in this transaction and did not receive any proceeds, as all shares were sold by the existing stockholder under its Form S-3 registration statement.
SBC Medical Group Holdings’ major shareholder Yoshiyuki Aikawa sold 3,100,000 shares of common stock in an underwritten secondary offering at $3.0225 per share. The underwriters also received a 45-day option to buy up to 465,000 additional shares. After the offering, Aikawa beneficially owns 84,304,460 shares, or about 82.2% of the 102,576,943 shares outstanding. He entered a 90-day lock-up restricting most additional sales following the April 21, 2026 closing.
SBC Medical Group Holdings Incorporated is registering the resale of 3,100,000 shares of its common stock by the selling stockholder pursuant to this prospectus supplement. The public offering price is $3.25 per share with the selling stockholder receiving the net proceeds; SBC will receive no proceeds. The underwriters have a 45-day option to purchase up to an additional 465,000 shares. Shares outstanding after the offering are stated as 102,576,943 (as of April 16, 2026). The offering is being managed by Maxim Group LLC (book-runner) and Roth Capital Partners (co-manager).
SBC Medical Group Holdings Incorporated discloses a resale offering by a selling stockholder of shares of its common stock; the company states it is not selling any shares hereunder and will receive no proceeds. The prospectus supplement lists a public-market reference price of $4.42 per share (closing price on April 16, 2026) and states there were 102,576,943 shares outstanding as of April 16, 2026. The filing identifies Yoshiyuki Aikawa as the selling stockholder and notes he and entities he controls held approximately 85.2% of voting power as of April 16, 2026. The underwriters have a 45-day option to purchase additional shares; underwriting discounts of 7.0% are disclosed in the underwriting table.